Multimodal imaging of neural progenitor cell fate in rodents by Waerzeggers, Y et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
Multimodal imaging of neural progenitor cell fate in rodents
Waerzeggers, Y; Klein, M; Miletic, H; Himmelreich, U; Li, H; Monfared, P;
Herrlinger, U; Hoehn, M; Coenen, H H; Weller, M; Winkeler, A; Jacobs, A H
Waerzeggers, Y; Klein, M; Miletic, H; Himmelreich, U; Li, H; Monfared, P; Herrlinger, U; Hoehn, M; Coenen, H
H; Weller, M; Winkeler, A; Jacobs, A H (2008). Multimodal imaging of neural progenitor cell fate in rodents.
Molecular Imaging, 7(2):77-91.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Molecular Imaging 2008, 7(2):77-91.
Waerzeggers, Y; Klein, M; Miletic, H; Himmelreich, U; Li, H; Monfared, P; Herrlinger, U; Hoehn, M; Coenen, H
H; Weller, M; Winkeler, A; Jacobs, A H (2008). Multimodal imaging of neural progenitor cell fate in rodents.
Molecular Imaging, 7(2):77-91.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Molecular Imaging 2008, 7(2):77-91.
Multimodal imaging of neural progenitor cell fate in rodents
Abstract
For clinical application of stem cell-based therapies, noninvasive detection of applied stem cells is of
high importance. We report on the feasibility of detecting implanted neural progenitor cells (NPCs)
noninvasively and follow their fate and functional status by sequential multimodal molecular imaging
and reporter gene technology. We investigated C17.2 cells stably expressing herpes simplex virus type
1-thymidine kinase (HSV-1-tk) and green fluorescent protein (gfp) (C17.2-tkIRESgfp = C17.2-TIG) or
HSV-1-tk, gfp, and firefly luciferase (luc) (C17.2-lucIREStkgfp = C17.2-LITG) and determined the
detection sensitivity of positron emission tomography (PET) and bioluminescence imaging (BLI) for
these cells in culture and in vivo in subcutaneous and intracranial glioma models. In addition, PET and
BLI were used to further investigate and follow the fate of implanted C17.2-LITG cells in an
intracranial glioma model. We show that both imaging modalities are sensitive in detecting reporter
gene expressing NPCs; however, PET, by the use of 9-[4-[(18)F]fluoro-3-hydroxymethyl)butyl]guanine
([(18)F]FHBG), detects NPCs only at sites of disrupted blood-brain barrier. Furthermore, both imaging
modalities can be used to detect stem cell fate and migration and indicate excessive proliferation and
aberrant migration. In conclusion, multimodal imaging can be used for longitudinal noninvasive
monitoring of grafted NPCs in rodents.
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For clinical application of stem cell-based therapies, non-invasive detection of applied stem 
cells is of high importance. In this study we report on the feasibility of detecting implanted 
neural progenitor cells (NPCs) non-invasively and follow their fate and functional status by 
sequential multi-modal molecular imaging and reporter gene technology. 
We investigated C17.2 cells stably expressing herpes simplex virus type-1-thymidine kinase 
(HSV-1-tk) and green fluorescent protein (gfp)(C17.2-tkIRESgfp = C17.2-TIG) or HSV-1-tk, 
gfp and firefly luciferase (luc)(C17.2-lucIREStkgfp = C17.2-LITG) and determined the 
detection sensitivity of positron emission tomography (PET) and bioluminescence imaging 
(BLI) for these cells in culture as well as in vivo in subcutaneous and intracranial glioma 
models. In addition, PET and BLI were used to further investigate and follow the fate of 
implanted C17.2-LITG cells in an intracranial glioma model.  
We show that both imaging modalities are sensitive in detecting reporter gene expressing 
NPCs, however, PET imaging by the use of 9-[4-[18F]fluoro-3-hydroxymethyl)butyl]guanine 
([18F]FHBG) only detects NPCs at sites of disrupted blood-brain barrier (BBB). Furthermore, 
both imaging modalities can be used to detect stem cell fate and migration and indicate 
excessive proliferation and aberrant migration. In conclusion, multi-modal imaging can be 
used for longitudinal non-invasive monitoring of grafted NPCs in rodents. 
 
 
 
 
 
 
 
 
 
 
Abbreviations: BBB: blood-brain barrier; BLI: bioluminescence imaging; CNS: central nervous system; 
[18F]FHBG: 9-[4-[18F]fluoro-3-hydroxymethyl)butyl]guanine; [124I]FIAU: 2'-fluoro-2'-deoxy-1ß-D-
arabinofuranosyl-5-[124I]iodouracil; GFP: green fluorescent protein; HSV-1-tk: herpes simplex virus type-1-
thymidine kinase; i.c.: intracranial; i.m.: intramuscular; i.p.: intraperitoneal;  i.v.: intravenous; luc: firefly 
luciferase; MRI: magnetic resonance imaging; NPCs: neural progenitor cells; PET: positron emission 
tomography; ROI: region of interest; s.c.: subcutaneous 
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Over the past decade extensive progress in stem cell research has led to the development of a 
large number of promising therapeutic approaches for various diseases. Transplantation of 
neural stem cells into damaged or degenerated brain, for instance, offers the possibility to 
treat diseases like Parkinson's (1), Alzheimer's (2) and Huntington’s (3) disease, traumatic 
brain injury (4, 5), spinal cord injury (6, 7), stroke (8-10) or multiple sclerosis (11). To treat 
neurodegenerative diseases pluripotent stem cells serve, theoretically, as a renewable source 
for the replacement of cells and tissues, and as vehicles to deliver bioactive molecules into 
tissue. The latter approach may also be of interest for the treatment of brain tumors.  
Useful molecules for stem cell-mediated delivery are growth factors (e.g. glial cell line-
derived neurotrophic factor - GDNF (12)), cytokines (e.g. interleukins – IL-4 (13) or IL-12 
(14)) and oncolytic or antineoplastic proteins (like viral thymidine kinase (15), bacterial 
cytosine deaminase (16, 17) or tumor necrosis factor-related apoptosis-inducing ligand (18)). 
Both cell replacement approaches and supply of therapeutically active substances are based 
upon the exceptional migratory capability of neural stem or progenitor cells (19-22). The 
capability of stem cells to migrate to sites of cerebral pathology was first demonstrated for 
intracranial gliomas (16), and was later also found in the setting of stroke (21, 23) and other 
central nervous system pathologies (4, 24, 25). 
The succes of stem cell-based therapeutic constructs depends besides on targeted migration 
also on their functionality within the target tissue over a prolonged period of time. Continuous 
non-invasive monitoring of the efficacy of cell-based therapies, which is of great clinical 
importance, should therefore cover both aspects: visualization and quantification of cell 
migration and functional cell status. Recent studies have used either bioluminescence imaging 
(18, 20) or magnetic resonance imaging (MRI) (21, 26, 27) for tracking of implanted stem 
cells. The transfer of results into the clinical routine based upon bioluminescence is restricted 
by the fact that this imaging modality cannot be applied in patients due to low tissue 
penetration of the optical signal, whereas data gained with MRI lack information on the 
functional status of implanted cells. 
 
The first aim of the current study was to directly compare the sensitivity of PET and BLI for 
the detection of transplanted cells in vivo and to follow the migration and fate of implanted 
NPCs non-invasively in vivo by means of sequential multi-modal imaging. The second aim 
was to use a setting for repeated non-invasive imaging which can be, at least in part, 
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transferred into clinical application. For the experiments in vivo we used a model murine NPC 
line (C17.2 cell line), a human glioblastoma cell line (human Gli36dEGFR glioma cells) 
known to form microsatellite lesions and a triple reporter gene construct allowing for 
simultaneous optical fluorescence (green fluorescent protein, gfp), bioluminescence (firefly 
luciferase, luc) and radionuclide imaging (HSV-1 thymidine kinase, HSV-1-tk). 
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Vector production and viral transduction 
Generation of pBABE-LITG 
The generation of pBABE-TIG has been described (28). The generation of pBABE-LITG is 
based on the construct pBABE-CITG (cytosine deaminase-IRES-tk39gly5gfp), which was 
generated by transferring the expression cassette CITG from pHSV-CITG (28) into pBABE-
puromycin. Thereafter, the luciferase gene including a 5’ 29 bp extension for advanced 
promoter recognition (Kozak sequence) was amplified by PCR out of pTA-luc (Takara Bio 
Europe/Clontech, Saint-Germain-en-Laye, France), generating 5’ XhoI and 3’ BglII 
restriction sites, respectively. This PCR product was ligated to a pBABE-ITG (IRES-tkgfp) 
backbone, generated by XhoI/BglII digestion of pBABE-CITG.  
 
Generation of C17.2-TIG and -LITG cells  
Retroviral packaging was performed as described (28). In brief, Phoenix cells (Nolan lab, 
Stanford, CA) were seeded (2 x 106 cells/well) in 3 ml of medium (10% FBS, 1% P/S). After 
24 h, chloroquine (Sigma, Taufkirchen, Germany) was added to each well (25 µM). This 
mixture was incubated for 5 minutes, followed by addition of 1 ml DNA mix containing 10 
µg pBABE-TIG or pBABE-LITG plasmid DNA and 120 mM CaCl2 in HBS buffer (pH 7). 
The cells were incubated for 7 h at 37°C before the medium was replaced to DMEM (10% 
FBS, 1% P/S) with subsequent incubation for 48 h at 34°C. Thereafter, retroviral particles 
were formed and, after centrifugation and removal of cellular debris, the medium served as 
infection medium. C17.2 cells were seeded (4x105/well in a 6 well plate) in 4 ml of DMEM 
containing 10% FBS and 1% P/S. After 24h, 2 ml medium were removed and 3 µl of 
polybrene (5 mg/ml, Sigma, Taufkirchen, Germany) was added to each well, followed by 
addition of 1 ml infection medium. Cultures were grown for 24 h, the medium was exchanged 
and cell culture was continued with fresh medium containing selection antibiotics (neomycin, 
puromycin). 
 
Cell culture 
Human Gli36dEGFR glioma cells were kindly provided by Dr. David Louis (Molecular 
Neurooncology Laboratory, MGH, Boston, MA). This cell line was established by retroviral 
transfer of a mutant epidermal growth factor receptor (D2-7EGFR) into the Gli36 human 
glioma cell line, enhancing its tumorigenic capacity (29). Mouse neonatal C17.2 NPCs, stably 
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transfected with the lacZ gene and the neomycin resistance gene, were kindly provided by Dr. 
Evan Snyder (Harvard Medical School, Boston, MA). Gli36dEGFR, Gli36dEGFR-TG17 
(Gli36dEGFR cells stably expressing a fusion protein of HSV-1-TK and GFP)(28) , C17.2-
TIG and C17.2-LITG cells were grown as monolayers in DMEM supplemented with 10% 
FBS (Gibco/Invitrogen, Karlsruhe, Germany) and 100 units/ml penicillin and 100 µg/ml 
streptomycin (1% P/S, PAA, Cölbe, Germany) at 37°C in a 5% CO
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2/95% air atmosphere. The 
cell culture for human Gli36dEGFR glioma cells contained puromycin (2 µg/ml) (Sigma, 
Taufkirchen, Germany), the cell cultures for Gli36dEGFR-TG17, C17.2-TIG and C17.2-
LITG cells contained puromycin and neomycin (G418; PAA, Cölbe, Germany) (2 µg/ml, 500 
µg/ml respectively). 
For MRI cell tracking experiments C17.2 cells were labeled with the iron oxide particles 
Sinerem® (generous gift of Guerbet, France) or Endorem® (Guerbet). For this purpose, cells 
were either labeled after 15 µg/ml Sinerem® were mixed with 8 µl Metafectene® (generous 
gift of Biontex Laboratories GmbH, Martinsried, Germany) according to (21) or by co-
incubation with 100 µl Endorem® (Guerbet) per ml medium. Co-incubation in the culture 
medium was performed for 12-16 h. Finally, cells were washed three times with phosphate 
buffered saline before implantation. 
 
Bioluminescence assay in culture 
The IVIS Imaging System 200 series (Xenogen Corp, Alameda, CA) was used for BLI 
acquisition. Serial dilutions of C17.2-LITG NPCs (10 – 10.000 cells/100 µl/well) were seeded 
into 96-well tissue culture plates. D-luciferin (2 mg/ml PBS, 20 µl/well; Synchem OHG, 
Altenburg, Germany) was added to each well just prior to BLI measurement. Imaging 
acquisition was set to 30 seconds. Gray scale photographic images and bioluminescence color 
images were superimposed using the Living ImageTM V2.50.1 software (Xenogen Corp, 
Alameda, CA). The same software was also used to manually draw regions of interest (ROI) 
over each well to determine mean luminescence (photons/second, p/s) ± standard deviation as 
a function of cell number. 
 
PET measurement of cell pellets 
PET measurements were performed on a micro-PET R4 scanner (Concorde Microsystems 
Inc., Knoxville, TN; 63 image planes, 2.0 mm FWHM). For determination of the cell 
detection limit of the microPET, serial dilutions of C17.2-TIG neural progenitor cells (1x103, 
5x103, 1x104, 5x104, 1x105, 5x105, 1x106, 2x106) were incubated with 170 µCi [18F]FHBG for 
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30 min. Afterwards cells were washed twice with PBS and resuspended in 100 µl PBS. 70min 
later a 10 min PET measurement of vials containing the [
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
18F]FHBG labeled C17-TIG cells 
was performed. To allow image co-registration and data evaluation, VINCI, a newly 
developed graphical image analysis tool, was used allowing for fast automated co-registration 
of multimodal imaging data (30). In order to obtain the activity in the vial from the PET 
measurement a volume of interest was drawn containing the entire vial and the total activity 
in the volume was calculated. 
 
Cell transplantations 
Animal procedures were in accordance with the German Laws for Animal Protection and 
were approved by the local animal care committee and the local governmental body 
(Bezirksregierung Köln).   
All surgical procedures were performed on spontaneously breathing male nude mice 
(HsdCpb:NMRI-Foxn1nu, Harlan-Winkelmann, Borchen, Germany) or male nude rats 
(Hsd:RH-Foxn1rnu, Harlan-Winkelmann, Borchen, Germany), anesthetized by intraperitoneal 
(i.p.) injection with ketamine (85 mg/kg bw; Ketavet®, Pharmacia &Upjohn Inc, Kalamazoo, 
MI) and xylazine (15 mg/kg bw; Rompun®, Bayer AG, Leverkusen, Germany). Furthermore, 
for intracranial injections, animals were fixed in a stereotactic frame (Model 900 small animal 
stereotaxic, David Kopf Instruments, Tujunga, CA). To determine the in vivo detection 
sensitivity of microPET for NPCs, C17.2-TIG cells (1x104, 1x105, 1x106 or 1x107 cells) or 
Gli36dEGFR-TG17 cells (1x105, 1x106 or 1x107 cells) were injected into pre-established 
subcutaneous (s.c.) or intracranial (i.c.) Gli36dEGFR gliomas. Glioma growth was initiated 
by injection of 5x106 Gli36dEGFR cells s.c. at the level of the shoulders (3-4 tumors/ animal) 
or 1x105 cells i.c., at the level of the striatum. 
For cell migration experiments, 1x105 Gli36dEGFR glioma cells were delivered into the right 
striatum and 2x105 C17.2-LITG cells into the left hemisphere. For co-injection experiments 
5x105 C17.2-LITG cells were mixed with 1x105 Gli36dEGFR cells and injected into the right 
striatum or 1x105 Gli36dEGFR cells were injected into the right striatum and 5x105 C17.2-
LITG cells were injected at the same coordinates 7 days later. Cells were suspended in 
DMEM and for s.c. injections 50 µl of the cell suspension were injected through a 30 Gauge 
needle (Becton Dickinson SA, Fraga, Spain) mounted on a 1 ml syringe (Terumo Europe, 
Leuven, Belgium); for i.c. injections 2 µl of the cell suspension were injected through a 26 
Gauge 10 µl microsyringe (Hamilton, Reno, NV). Striatal coordinates were the following: 
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anterioposterior 0 mm, mediolateral -/+ 2.5 mm, ventral 3 mm. All coordinates were selected 
relative to bregma and ventral coordinates relative to dura. 
 
Radiosynthesis of [124 I]FIAU and [18F]FHBG 
The specific marker substrates for HSV-1-TK 2'-fluoro-2'-deoxy-1ß-D-arabinofuranosyl-5-
[124I]iodouracil ([124I]FIAU) and 9-[4-[18F]fluoro-3-hydroxymethyl)butyl]guanine 
([18F]FHBG) were produced as described (28, 31).  
 
Multi-modal imaging 
BLI 
Bioluminescence acquisition and analysis were performed with the IVIS 200 Imaging System 
and the Living ImageTM V2.50.1 software (both Xenogen Corp, Alameda, CA). Animals were 
i.p. injected with D-luciferin (20 mg/ml PBS, 100µl/animal) 10 min prior to signal acquisition 
(30, 60 and 120 s) which took place under 2.5% isoflurane anesthesia. Gray scale 
photographic images and bioluminescence color images were superimposed and ROIs were 
manually drawn over the brain. The area of the ROI was kept constant over the entire duration 
of the experiments and the total signal intensity within the ROI was recorded (total flux, p/s). 
 
PET 
PET imaging was performed using a microPET R4 scanner (Concorde Microsystems Inc., 
Knoxville, TN; 63 image planes, 2.0 mm FWHM) as described (28, 32). Tracer injection and 
image acquisition were performed on spontaneously breathing animals anesthetized with 
halothane (1.5%) in O2:N2O (35:65%). No tracer injection was performed when [124I]FIAU 
pre-labeled cells were used. Radiotracer (no-carrier-added [18F]FHBG, 300 µCi/rat, 200 
µCi/mice respectively) was administered i.v. into the tail vein. Temperature was maintained at 
37°C and monitored throughout the PET measurements. Mice emission scans were obtained 5 
min (10 min duration) and 150 min (30 min duration) after tracer injection. Early scans (after 
5 min tracer incubation) were used for co-registration, late scans (after 150 min tracer 
incubation) for detection of specific tracer accumulation. Rat emission scans were obtained 
150 min (30 min duration) after tracer injection. Images were reconstructed using Fourier 
rebinning (FORE) and 2D-filtered back projection (2DFBP; microPET). For quantification of 
images, a reference standard sample of radiotracer was placed within the field of view of the 
PET scanner. To allow image co-registration and data evaluation VINCI was used. Data 
evaluation was based on a ROI analysis of PET images to determine maximal radioactivity 
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concentrations within tumors. After background subtraction (contralateral hemisphere for i.c. 
experiments or mediastinum for s.c. experiments), data were decay corrected and divided by 
the total injected dose (ID) to represent percentage ID dose per gram (%ID/g). 
 
MRI 
Localization of tumor growth was performed by MRI after intraperitoneal administration of 
approximately 70 µl Gd-DTPA (500mM, Magnevist®, Schering, Berlin, Germany). Animals 
were anesthetized using 1.5% halothane in O2:N2O (35:65%). Temperature was maintained at 
37°C and monitored throughout the MRI measurements. All MR images were acquired using 
a Biospec 7.0 Tesla small animal scanner (Bruker BioSpin, Ettlingen, Germany; horizontal 
bore, 30 cm) equipped with actively shielded gradients (200mT m-1). Purpose-built radio-
frequency coils were used (12 cm Helmholtz coils for excitation and a 2.5 cm surface coil for 
detection). Following two-dimensional localization scans, three-dimensional gradient-echo 
scans (FLASH) with T1-weighting were acquired. The acquisition parameters were: spatial 
resolution 70x167x156  µm3, field-of-view  18x16x10 mm3, TR=70ms, TE=5ms, flip angle 
60°. Images were processed using Paravision3.2 (Bruker Biospin). The total experimental 
time was 30-40 min per MRI study. Co-registration of MR images with respective PET 
images was performed using the in-house developed software VINCI. 
For MRI cell tracking experiments, 3D T2*-weighted MR images were acquired as above 
using the following parameters: FLASH sequence, spatial resolution 80x80x80 µm3, 
TR=200ms, TE=20ms, flip angle 30°. 
 
Immunostaining 
For immunostaining, 2 x105 cells were seeded on coverslips placed in 24 wells and incubated 
for 24 hours in DMEM (10% FBS, 1% P/S). The following day cells were washed with PBS 
(3 x 5 min), fixed with paraformaldehyde (4%, 20 min) and washed again with PBS (3 x 5 
min). Cells were permeabilized with Triton X-100 (0.2%) in PBS (3 min) and washed again 
with PBS (3 x 5 min). Unspecific binding of antibodies was prevented by blocking cells with 
BSA (3%, 60 min). Thereafter, cells were washed with PBS/0.3% BSA (3 x 5 min), followed 
by a 90 min incubation with the first antibody in PBS/0.3% BSA. After washing the cells 
again for 5 x 5 min with PBS/0.3% BSA, the second antibody was added in PBS/0.3% BSA. 
Cells were washed with PBS (5x) and bidest (1x), then coverslips were removed from 24 
wells, put on glass slides and sealed using Citifluor (Citifluor Mountant Medium, Citifluor 
Ltd, Leicester, UK). The antibodies used were rabbit anti-chemokine receptor 4 (anti-
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CXCR4) (Abcam plc, Cambridge, UK) and rabbit anti-nestin (Chemicon, Temecula, CA). 
The secondary antibody was Cy3/FITC-coupled goat-anti rabbit (Amersham, GE Healthcare 
Europe GmbH, Munich, Germany). 
 
Histology and image validation 
Animals were sacrificed by transcardial perfusion with 4% paraformaldehyde at the time 
point of neurological impairment for the migration studies or after completion of the imaging 
protocol for the detection sensitivity studies. Brains were removed, suspended in 30% sucrose 
for 3 days and snap-frozen in 2-methylbutane chilled on dry ice. Cryostat sections (12µm) 
were stained with hematoxylin and eosin (H&E; Merck, Darmstadt, Germany) and X-Gal 
(Sigma-Aldrich, Munich, Germany) to identify lac-Z expressing NPCs as described (33). 
 
Experimental protocol 
In vivo detection sensitivity of microPET for NPCs 
In a first set of experiments (nude rats; n=4), [124I]FIAU pre-labeled C17.2-TIG cells (1x104, 
1x105, 1x106 cells) were injected into 11 d old s.c. gliomas (Fig. 1A). These concentrations 
corresponded to 1.33, 11.82 and 108.82 µCi of radioactivity, respectively. Injection of 
DMEM served as negative control. During the following 7 days serial PET measurements 
were performed to detect the level of FIAU-derived signal. 
In a second set of experiments (nude mice; n=6), C17.2-TIG cells (s.c.: 1x105, 1x106, 1x107; 
i.c.: 1x105 cells) or cells of the positive control cell line Gli36dEGFR-TG17-R4 (s.c.: 1x105, 
1x106, 1x107; i.c.: 1x105 cells) were injected into pre-established 10 d old s.c. or 5 d old i.c. 
gliomas. Injection of DMEM served as negative control (Fig. 1B). 18F-FHBG-PET 
measurements (300 µCi [18F]FHBG/animal) 24 and 48 h after stem cell injection were 
performed to detect the localization and intensity of TK-signal. 
 
Multimodal imaging of NPCs  in an intracranial glioma model 
In a third set of experiments, C17.2-LITG cells were inoculated into the left striatum of nude 
mice (n=5; Fig. 1C I) and their migrational capacity towards the contralateral tumor bearing 
hemisphere was monitored by serial BLI and [18F]FHBG-PET measurements. In n=3 of these 
animals the glioma cell injections (Gli36dEGFR cells) into the right striatum were performed 
on the same day as the stem cell injections, in n=2 of these animals glioma cells were first 
allowed to proliferate for one week and then the stem cells were inoculated (Fig. 1C I). In 
n=2 animals C17.2-LITG cells were implanted into preestablished gliomas (Fig. 1C II), and 
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in n=4 animals C17.2-LITG cells were mixed and co-implanted together with Gli36dEGFR 
cells (Fig. 1C III)(see below). In control animals (n=2) only injection of C17.2-LITG cells in 
the left striatum was performed (Fig. 1C IV). Bioluminescence measurements were 
performed within 48 h after stem cell inoculation and thereafter at 2-3 day intervals. PET 
measurements were performed at d0, d16 and d22 after stem cell inoculation. To verify tumor 
growth, MR images were acquired between d6 and d20 after tumor cell inoculation. 
 
To our knowledge, detection of neural stem cells (NSCs) in the central nervous system with 
[18F]FHBG-PET imaging has not been addressed in previous studies yet. For the current study 
we hypothesized that only at the site of glioma proliferation, where intrinsic tumor induced 
opening of the BBB takes place, it would be possible to detect HSV-tk-tk+ neural progenitor 
cells by means of [18F]FHBG-PET imaging. Therefore, in a fourth set of experiments, we 
injected C17.2-LITG cells into pre-established gliomas (n=2; Fig 1C II)), or as a mixture 
together with glioma cells (n=4; Fig. 1C III) and monitored their behavior over time with BLI 
and [18F]FHBG-PET. MRI experiments after Gd-DTPA administration were performed for 
the evaluation of the integrity of the BBB. 
In an independent set of animals (n=6) iron oxide labeled C17.2 cells were injected into the 
left striatum and glioma cells into the right striatum and NPC migration was monitored with 
MRI. 
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Characterization of transduced neural progenitor cells in culture. 
Stably transduced NPCs (C17.2-TIG and C17.2-LITG) were compared to the parental cell 
line (C17.2) regarding growth behavior, cell morphology and the expression pattern of nestin 
as specific progenitor cell marker and CXCR4, an alpha-chemokine receptor specific for 
stromal cell-derived factor 1 (SDF-1), as a marker for migration. No significant differences 
were found in cultured cells with regards to growth characteristics and morphology up to 
passage numbers used for implantation (<40). When analyzing higher passage numbers (>60), 
CXCR4 staining significantly decreased in C17.2-LITG cells (data not shown). 
 
Detection sensitivity of microPET for NPCs expressing viral thymidine kinase in cell 
culture. 
The microPET detection sensitivity for C17.2-TIG cells pre-labeled with [18F]FHBG was 
analyzed by measuring cell numbers ranging from 1x103 to 2x106. Figure 2A shows the 
correlation between cell numbers and PET signal intensity displayed as counts/min (cpm) and 
the corresponding PET image indicating that approximately 5x103 cells can be visualized 
when located in a certain volume of interest (100 µl).  
 
Detection sensitivity of BLI for NPCs expressing firefly luciferase in cell culture. 
To determine the detection limit of IVIS 200 for our model NPCs cell line expressing firefly 
luciferase (C17.2-LITG), with cell numbers ranging from 10 to 1x104, were investigated in 
triplicate. Figure 2B demonstrates the relationship between cell number and bioluminescence 
signal indicating that as few as 100 cells can be detected by the IVIS 200 system.  
 
Detection sensitivity of microPET for NPCs expressing viral thymidine kinase in vivo. 
In the first set of experiments [124I]FIAU pre-labeled C17.2-TIG cells were injected into 
subcutaneous growing gliomas. Immediately after cell implantation the signal of the 
[124I]FIAU pre-labeled cells was visible for all used cell concentrations in all animals, with 
the signal intensity being proportional to the number of implanted cells (Fig. 3A). Signal 
intensity decreased over time so that only the highest cell number could still be detected 6 
days after intratumoral injection. This decrease in [124I]FIAU signal over time was faster than 
the decay of radiotracer. 24 h after injection the remaining radioactivity was 20%, ~40%, and 
60% of the expected value for 1x104, 1x105, and 1x106 cells, respectively (Fig. 3B).  
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18F]FHBG accumulation became only visible for the highest cell number (1x107 cells) of 
both cell lines 24 and 48 h after intratumoral injection in 1 out of 4 tumors containing this cell 
number (Fig. 3C). 
C17.2-TIG or Gli36dEGFR-TG17 cells (1x105 cells) injected into intracranial growing 
gliomas were not detected by [18F]FHBG-PET.  
 
Multimodal imaging of NPCs in an intracranial glioma model 
In the third set of experiments, transplanted C17.2-LITG cells were detected as an almost 
spherical BLI signal (Fig. 4, upper row). From approximately d8, a tail at the medial edge of 
the bioluminescence signal was observed indicating possible migration of C17.2-LITG cells 
towards the tumor in the contralateral hemisphere. In none of the animals a complete shift of 
the stem cell-mediated BLI signal to the contralateral side could be detected (Fig. 4, upper 
row). This result was independent of the timing of NPC injection relative to tumor cell 
injection. In all mice, tumor growth was confirmed by MR imaging (Fig. 4, middle row). 
Stem cells inoculated in the left striatum could not be detected by [18F]FHBG-PET (Fig. 4, 
lower row) due to the inability of this radioisotope to cross the intact BBB. Even at later time 
points, no specific [18F]FHBG accumulation became visible, neither in the primary injection 
site nor within the area of the contralateral tumor (Fig. 4, lower row). Histological analysis 
confirmed the restriction of C17.2-LITG cells to the injection site (Fig. 8A). 
In the fourth set of experiments with unilateral intracerebral injections of NPCs and tumor 
cells, in all animals C17.2-LITG cells could be detected with BLI and [18F]FHBG-PET (Fig. 
5). The bioluminescence signal intensities increased over time both in the mix injection 
experiments and the intra-tumoral injection experiments. This increase in signal intensity was 
also observed by [18F]FHBG-PET. The average increase of the luminescence signal was 19.6-
fold for the intratumoral injections after 1 week. In the mixed implantation experiments the 
average increase over the first 2 weeks was 11.0-fold (Fig. 6). In contrast, in the third 
experiment with bihemispheric injections there was only a 1.7-fold increase in the 
bioluminescence signal by 2 weeks. Fig. 8B shows representative images from one animal 
with injection of C17.2-LITG cells mixed with Gli36dEGFR cells. These images show that at 
the time point of sacrifice, 14d after injection of the cell mixture, tumor growth was more 
extensive than the distribution of the NPCs within the tumor. 
In control animals (n=2) who received C17.2-LITG cells into the left striatum, no migration 
of neural progenitor cells towards the unaffected right hemisphere was observed. However, 
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uncontrolled migration of C17.2-LITG cells in the direction of the cerebellum could be 
observed in both animals. This aberrant migration was preceded by a clear increase in 
bioluminescence signal intensity. In one animal the migration became apparent 79 d after 
C17.2-LITG inoculation, and lasted for more than 2 months before the animal deceased (Fig. 
7A). In the second animal, C17.2-LITG migration towards the cerebellar hemispheres took 
place 2 weeks after cell inoculation. At 3 weeks progenitor cells were also localized at the 
level of the thoracolumbar spine resulting in paraplegia (Fig. 7B).  
Furthermore, aberrant progenitor cell migration could also be detected in one animal of the 
intra-tumoral injection group. NPCs became visible around the cerebellum 5 d after cell 
inoculation (data not shown).  
Although MRI served primarily the purpose of monitoring tumor growth and location, 
attempts were made to monitor cell migration by MRI after labeling them with iron oxide 
particles. These experiments were not successful due to the short migration distance of iron 
oxide labeled cells. Due to the strong susceptibility effect of the contrast agent in T2*-
weighted MR images, migrating cells were not distinguishable from the large reservoir of 
non-migrating cells. Utilization of lower concentrations of the iron oxide particles and/ or 
utilization of T2-weighted MRI for the suppression of the susceptibility effect were not 
sensitive enough for the detection of the small clusters of migrating cells (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
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In this study we investigated the feasibility of different molecular imaging modalities to 
detect cultured and implanted NPCs engineered to express specific imaging genes. Using 
modified pBABE-retroviral constructs, C17.2 NPCs were engineered in culture to 
proportionally co-express a fluorescent gene (gfp) together with PET (HSV-1-tk) and/or BLI 
(luc) imaging genes (C17.2-TIG or C17.2-LITG).  
While BLI was found to be the more sensitive tool, detecting up to 100 cells expressing 
firefly luciferase in cell culture, tk-expressing cells could be detected with PET-imaging too. 
The in cell culture detection limit for PET was 5x103 cells labeled with [18F]FHBG. In vivo, 
1x104 intratumorally implanted [124I]FIAU pre-labeled C17.2-TIG cells could be detected, 
while only 1x107 cells could be detected using [18F]FHBG-PET after intratumoral 
implantation.  
The second aim of this study was to non-invasively follow the fate of C17.2-LITG NPCs in 
an i.c. glioma model. The use of BLI enabled the detection of inoculated stem cells in all 
implantation paradigms, whereas [18F]FHBG-PET only detected NPCs localized at sites of 
disrupted BBB. MRI was recorded to navigate the PET or BLI signal orientation within the 
brain morphology. Tumor attracted cell migration could only be faintly detected with BLI, 
whereas aberrant cell migration in the direction of cerebellar hemispheres and even of 
thoracolumbar spine could be clearly detected, both in tumor bearing and in control animals. 
Moreover, in co-injection experiments, BLI signals steadily increased in intensity over time as 
opposed to the BLI signals in bihemispheric injection experiments, most likely due to 
excessive progenitor cell proliferation.  
Altogether our data demonstrates that multi-modal imaging of the fate of neural progenitor 
cells inoculated into the rodent brain is feasible using reporter gene technology. BLI serves 
the higher sensitivity for detecting luc-expressing cells especially in conditions where the 
BBB is intact. In conditions where the BBB is disrupted, [18F]FHBG-PET also serves for 
localization for TK-expressing cells. Sequential, non-invasive imaging may serve as a safety 
switch for early detection of aberrant cell migration and excessive cell proliferation.  
 
Over the past decades several imaging technologies for repetitive and non-invasive imaging 
of the fate of implanted cells after their administration into an organism have been developed. 
Among these technologies BLI, PET and MRI are mostly used in experimental animal 
studies. Each of these technologies has its intrinsic advantages and disadvantages (34, 35). All 
three modalities have been used to track the migratory capacity of implanted cells. Whereas 
stem cell migration within the central nervous system (CNS) has been described both by MRI 
- 15 - 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
and BLI, PET imaging has up to now only been used to image the whole body distribution of 
adoptively transferred immune T lymphocytes (36, 37), ex-vivo labeled tumor cells (38), 
mesenchymal stem cells (39) or the intratumoral distribution of bone-marrow derived 
progenitor cells in an intracranial rat glioma model (40). In the latter study, PET was 
successfully used to non-invasively detect intratumorally injected tk-expressing bone marrow-
derived tumor-infiltrating cells and to monitor their therapeutic efficacy after ganciclovir 
treatment. No attempts were made to study the feasibility of PET to non-invasively image 
tumor attracted stem cell migration or long-term behavior of injected stem cells, which were 
some of the aims of this study. MRI has been used to detect stem cell migration within the 
CNS under several conditions; normal development (41), stroke (21, 23, 26), tumor growth 
(42), traumatic brain and spinal cord injury (27). BLI has been used to detect stem cell 
migration towards growing gliomas (18, 43) or stroke regions (20) and to monitor the 
magnitude and timing of the therapeutic effect of stem cell mediated delivery of pro-apoptotic 
proteins (18).  
 
Our data indicate that reporter gene labeled NPCs can be detected not only with BLI but also 
using PET with signal intensities being proportional to cell number in both cases.  
The detection sensitivity of BLI for serial dilutions of C17.2-LITG cells was 100 cells. The 
detection sensitivity of µPET for serial dilutions of [18F]FHBG pre-labeled C17.2-TIG cells 
was 5x103 in 100 µl. When ex-vivo [124I]FIAU pre-labeled C17.2-TIG cells were injected into 
pre-established s.c. gliomas, the lower detection limit was 1x104 cells. In contrast, only 1x107 
of  in-vivo 18F-FHBG labeled C17.2-TIG cells could be detected. When the [124I]FIAU signal 
was registered over time, the decrease of the signal intensity was more rapid than the decay of 
the radiotracer. This finding was constant in all analyzed cell numbers. Because single cells 
are the carriers of radioactivity, cell death means wash-out of the tracer. Related to the here 
described observation, the discrepancy between expected and measured radioactivity can be 
interpreted as progressive cell death after intratumoral injection. 
In a similar experiment, analyzing HSV-1-tk-expressing N2a murine glioma cells, Su et al 
(44) found that using the µPET P4 scanner the limit of detection was 1x105 cells in 200 µl for 
[18F]FHBG pre-labeled cells, in culture as well as in vivo and 1x106 in 100 µl for in vivo 
[18F]FHBG labeled cells. The better in vitro detection properties of the C17.2-TIG cells used 
in our study might be due to a higher degree of TK-expression per cell, whereas the 
intratumoral administration of cells in our study might have led to a decreased degree of cell 
survival.  
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The fluorescent protein included in the imaging constructs was used to check transduction 
after generating stable cell lines under the microscope. In vivo fluorescence imaging was not 
performed because of the unfavourable spectral properties of GFP with high light scatter and 
absorption (45). For this purpose a more red shifted protein or dye would be more appropriate 
as has been shown previously for superficial locations (46). 
 
The C17.2 cell line used in the current study is a model clonal NPC line derived from mouse 
neonatal cerebellum, immortalized with the c-myc oncogene and stably expressing lacZ (47). 
This C17.2 cell line has previously been characterized as a transgene-expressing cell line 
fulfilling the strict operational definition of a stem cell (48, 49).  
Furthermore, in different studies in the past numerous research groups have assessed the 
exceptional migratory ability and the potential of this cell line to be successfully transfected 
with various therapeutic genes without losing its stem cell properties (16, 18, 20, 41, 43, 50). 
 
In published C17.2 tracking experiments using BLI for stem cell detection, a 50 to 100% shift 
of the stem cell-derived BLI signal from the site of cell injection to the contralateral 
pathological hemisphere has been reported (18, 20, 43). In contrast, only a minor shift of stem 
cell-derived BLI signal to the contralateral hemisphere was detected in our experiments. The 
number of animals investigated in the current study (n=5) was comparable with the numbers 
investigated by Tang et al (n=5) (43), Shah et al (n=16) (18) and Kim et al (n=9) (20). In 
agreement with our experiences, other investigators also observed that although many 
intracranially inoculated NSCs demonstrated robust migratory activity and tumor-tracking 
capabilities, a significant proportion of transplanted NSCs did not exhibit this migratory 
capacity and remained localized at the site of initial intracranial injection (14).  
Further analysis of the subpopulation of migrating NSCs revealed that the tumor-tropic cell 
population comprised of progenitor cells that had initiated, but not completed, pathways 
towards astrocytic differentiation as they stained positively for the astroglial precursor 
markers A2B5 and glial fibrillary acidic protein (GFAP) but negatively for the differentiated 
glia markers excitatory amino acid transporter 1 and 2 (EAAT1 and EAAT2) (51). 
Additionally, tumor-tracking NSCs strongly expressed CXCR4, the cell surface receptor for 
SDF-1 and tumor-tracking abilities could be significantly inhibited by blocking CXCR4. It 
has recently been shown that the production of SDF-1 by glioma cells, the only known ligand 
for CXCR4, correlates with the histological grade, tumor cell survival, and invasiveness (52, 
53). Immunohistochemical analysis of the C17.2 cell lines used in the current study showed 
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only minimal staining for CXCR4 and even absent staining in cells with high passage 
number. This is one possible explanation why intracranially implanted C17.2-LITG cells did 
not migrate extensively towards contralateral growing gliomas in our experiments. However, 
the C17.2 cells used exhibited migrational potential towards the cerebellum, independent of 
glioma proliferation. Because this neural progenitor cell clone was initially derived from 
developing mouse cerebellum (47), it is feasible that cerebellar – chemotactic - cues made 
C17.2 cells migrate towards this brain region where they, from a developmental point of 
view, belong.  
 
As stated above only limited data currently exists on cell trafficking using PET. In general, 
the application of HSV-1-tk as PET-marker within the CNS is limited by the fact that 
marker/reporter probes for this system do not significantly penetrate the BBB (54). Thus, in 
order to be able to detect C17.2-LITG cells within the brain by specific accumulation of 
[18F]FHBG, these cells have to be localized in a region with BBB disruption, in our 
experiments corresponding to regions with tumor induced opening of the BBB as confirmed 
by gadolinium enhanced MR images. Under these conditions we were indeed able to detect 
intracranial localized NPCs. However, it should be pointed out that results of the experiments 
with 2x105 C17.2-LITG cells (migration) and 5x105 C17.2-LITG cells (intratumoral injection) 
might not be directly comparable due to different cell numbers used. 
To overcome the problem of  limited BBB penetration, several research groups are exploring 
methods to improve the transport rates of these marker/reporter probes across the BBB, e.g. 
by creating new radiolabeled HSV-1-tk substrates with increased lipophylicity which 
facilitates passive diffusion of the radiotracer through the BBB (55) or by creating new 
reporter gene/reporter substrate systems, like the xanthine phosphoribosyltransferase (XPRT)-
xanthine system. The feasibility, sensitivity and specificity of this system have already 
successfully been tested in an intracranial glioma model (RG2) with almost intact BBB using 
[14C]xanthine and quantitative autoradiography (56).  
The application of reporter probes that readily cross the intact BBB will significantly enhance 
the potential of PET to study CNS pathologies which do not induce BBB disruption, like 
neuropsychiatric disorders or in which there is only little or inhomogeneous BBB damage, 
like in gliomas (57-59).   
 
Bioluminescence imaging is a semi-quantitative imaging modality (60, 61). We confirmed for 
the transgenic cell line C17.2-LITG used here a linear dependency between cell number and 
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the rate of photon emission. In contrast to bihemispheric injection experiments, we observed a 
steadily increasing BLI signal in co-injection experiments. By extrapolation of our cell culture 
data, this observation means that the C17.2-LITG cell number steadily increased in the co-
injection experiments, whereas the stem cell number remained more or less constant in the 
bihemispheric injection experiments. Theoretically two mechanisms can explain the behavior 
of C17.2 cells that come in contact with glioma cells: excessive proliferation or tumorigenic 
transformation of the progenitor cells. Multiple growth factors are known to be expressed in 
gliomas. Among those are fibroblast growth factor 1 and 2 (FGF-1 and FGF-2); plateled-
derived growth factor AA and BB (PDGF-AA and PDGF –BB); scatter factor/hepatocyte 
growth factor (SF/HGF); insuline-like growth factor 1 and 2 (IGF-1 and IGF-2); transforming 
growth factor α , β1 and β2 (TGF-α, TGF-β1 and TGF-β2); pleiotrophin (PTN) and midkine 
(62, 63). Several of these factors have been implicated in the stimulation of glioma cell as 
well as stem cell migration (64) , survival and proliferation (65-67). Furthermore, it has 
recently been shown that PDGF-AA has the potential to induce proliferation of stem cells (B 
cells) from the subventricular zone and even generate large hyperplasias with some features of 
gliomas (68).  
The observation of similarities between the self-renewal mechanisms of stem cells and cancer 
cells has led to the new concept of the cancer stem cell. The cancer stem cell hypothesis of 
tumor origin was first reported in leukemia (69) and has been extended to other tumor entities, 
like prostate cancer (70), breast cancer (71), bone sarcoma (72), liver cancer (73), melanoma 
(74) and brain tumors (75) including glioblastoma (76). 
A recent review addresses the possibility that cancer stem cells originate from cell fusion or a 
horizontal gene-transfer process (77). Therefore, theoretically, in the current co-injection 
experiments, cell fusion between C17-LITG cells and Gli36dEGFR cells may have occurred. 
However, it must be notified that the sole implantation of C17.2-LITG progenitor cells in 
control animals also led to an increase in bioluminescence signal intensity preceding 
uncontrolled migration of the cells. The increase in signal intensity in this region again 
implicates the proliferation of these cells. Both, uncontrolled migration and proliferation of 
NPCs have not been described in similar studies dealing with C17.2 migration towards brain 
lesions (18, 20, 43). At least in one animal of the present study this might be due to the longer 
investigation time (144 d) compared to other studies. Our data indicate that the use of NPCs 
in cell-based therapies should be performed carefully as the proliferation potential of these 
cells might be reactivated within an unpredictable time frame after transplantation.  
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Further analysis of both progenitor cell - tumor cell interaction and progenitor cell 
migration/proliferation stimuli are necessary and currently under investigation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
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In conclusion, we have engineered NPC lines, C17.2-TIG and C17.2-LITG, to express a dual 
or triple reporter gene construct for serial, non-invasive monitoring of cell fate with 
bioluminescence imaging and positron emission tomography in living animals. Our data 
indicate that molecular imaging should be used as a safety switch for early detection of 
aberrant cell migration and excessive cell proliferation. By using of PET as a non-invasive 
imaging modality a direct transfer into the clinical setting is possible. 
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Fig. 1: Implantation scheme of in vivo experiments. 
A: Implantation scheme of [124I]FIAU prelabeled C17.2-TIG cells or DMEM injected intro 
pre-established s.c. Gli36dGEFR gliomas in 4 rats. 
B: Implantation scheme of C17.2-TIG cells, Gli36dEGFR-TG17 cells or DMEM into pre-
established s.c. or i.c. Gli36dEGFR gliomas in 6 mice. 
C: Implantation scheme of C17.2-LITG cells into mouse striatum: I. bihemispheric injection, 
II. intratumoral injection, III. mixed injection, IV. control injection. 
D: Figure legend. 
 
Fig. 2: Characterization of transduced NPCs in vitro. 
A: microPET image of vials containing different concentrations of [18F]FHBG labeled C17.2-
TIG cells (left panel) and the corresponding graph demonstrating the linear correlation 
between [18F]FHBG labeled C17.2-TIG cell number and PET signal (right panel). 
B: Bioluminescence image of different concentrations of C17.2-LITG cells in a 96 well after 
addition of D-Luciferin (left panel) and  the corresponding graph demonstrating the linear 
correlation between C17.2-LITG cell number and bioluminescence signal (right panel). 
 
Fig. 3: In vivo detection sensitivity of µPET for NPCs. 
A: µPET measurements of [124I]FIAU pre-labeled C17.2-TIG cells (1x104, 1x105 and 1x106 
cells) followed over 3 d. 
B: Evolution of [124I]FIAU signal intensity of the used cell concentrations over time, 
expressed as percentage of the expected signal when only tracer half life is taking into 
account. 
C: [18F]FHBG-PET performed 48 h after injection of 1x107 C17-TIG or Gli36dEGFR-TG17 
cells into pre-established s.c. Gli36dEGFR gliomas. Gli36dEGFR-TG17 s.c. tumors served as 
positive controls.  
 
Fig. 4: Multi-modal imaging of NPC migration towards the contralateral tumor 
bearing hemisphere. 
Multi-modal imaging of a representative animal in which C17-LITG cells were injected into 
the left striatum at the same day as glioma cell inoculation into the right striatum. 
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Upper row: BLI signal over the brain at 1, 8, 13 and 20 d post implantation. 
Middle row: Gadolinium enhanced T1 magnetic resonance image at 22 d post transplantation. 
The cross in the left panel focuses the injection tract of the progenitor cells; the cross in the 
right panel focuses the growing glioma. 
Lower row: [18F]FHBG-PET image at 22 d post transplantation, matched to the MR image 
displayed in the middle row. After 150 min tracer incubation no specific [18F]FHBG 
accumulation is visible at the site of stem cell inoculation (left panel), neither at the site of 
glioma proliferation (right panel). 
 
Fig. 5: Histological evaluation. 
A: H&E (a) and X-Gal staining (b and c) of one representative animal with 2x105 C17-LITG 
cells injected contralateral to an established glioma. (a) Tumor in the right striatum; (b) NPCs 
(blue) stay localized at the injection site and did not migrate to the contralateral tumor; (c) 
higher magnification of (b). The animal was sacrificed 20 days after glioma cell inoculation.  
B: H&E (a) and X-Gal staining (b and c) of one representative animal with injection of 5x105 
C17-LITG cells mixed with 1x105 glioma cells. (a) Tumor in the right striatum; (b) NPCs 
(blue) spread within the tumor but did not migrate to the tumor border or to the adjacent brain 
parenchyma; (c) higher magnification of (b). The animal was sacrificed 14 days after injection 
of the cell mixture. 
 
Fig. 6: Multi-modal imaging of NPCs. 
Displayed are data from one representative animal with injection of NPCs within a pre-
established glioma (A) and from one representative animal with injection of NPCs mixed with 
glioma cells (B). 
Upper row: BLI signal over the brain at 0, 2, 5, 9 and 13; resp. 0, 5, 13 and 15 d post 
implantation. 
Second row: Gadolinium enhanced T1 magnetic resonance image at 7 d post transplantation. 
The cross focuses the growing glioma. 
Lower rows: [18F]FHBG-PET image at 7 and 13 d post transplantation, matched to the MR 
image displayed in the second row. After 150 min tracer incubation specific [18F]FHBG 
accumulation is visible at the site of glioma proliferation in both injection paradigms (A and 
B). The BLI signal intensity increase between d5 and d15 in the mixed injection paradigm is 
also reflected in an increased [18F]FHBG uptake between d7 and d13 (B). 
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Data are displayed as the mean rate of total photon emission (p/s ± SD) in the three injection 
paradigms (NPCs injected contralateral to glioma cells, within a growing glioma or as a 
mixture with glioma cells). 
 
Fig. 8: Bioluminescence imaging of NPCs injected into the unaffected brain. 
C17-LITG cells were injected into the left striatum and their behavior over time was 
monitored with optical imaging. 
A: NPC migration in the direction of the cerebellar hemispheres (red arrow) could be 
demonstrated starting from day 79 post injection in this animal. 
B: in this animal cerebellar migration was already obvious 13 d after injection (red arrow); at 
3 weeks NPCs also localized at the level of the thoracolumbar spine (green arrow). 
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